TUSTIN, CA -- (Marketwire) -- 08/16/10 -- Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today Mr. Mathi Senapathi has joined the Company's executive management team as Director of Manufacturing, responsible for the manufacturing of RPC's Onko-Sure® in vitro diagnostic (IVD) cancer test kits.

Mr. Senapathi has over 18 years of diverse pharmaceutical industry experience, including roles in laboratory quality control and research, quality assurance, advanced clinical and anatomic pathology, regulatory compliance and systems monitoring and control for GLP, GMP and GCP; and program monitoring for ISO9001, ISO 13485.2003 drug safety evaluation.

"Mathi is a strong addition to RPC's management team and his appointment speaks volumes to RPC's investment in the continued commercialization for Onko-Sure," said Mr. Douglas MacLellan, Chairman and CEO of Radient Pharmaceuticals. "We continue to advance our manufacturing operation in support of our domestic and international sales pipeline. Mathi will be a major contributor to current and future manufacturing efforts and I am pleased to welcome him to the team."

Most recently Mr. Senapathi worked as Director of Quality Assurance at Pathogenesys. In this position, Mr. Senapathi's scope of responsibility included establishing and overseeing quality systems and compliance programs as they related to GLP and ISO9001, ISO 13485.2003. He also held the role of FDA and research compliance audit liaison. Prior to this Mr. Senapathi was employed with Allergen and Meyer Pharmaceuticals where he held various progressively responsible roles in manufacturing; risk management; regulatory and SOP training; assay development, validation and data collection and maintenance; and clinical trials. Mr. Senapathi holds a Master's Degree in Philosophy; Master's Degree in Arts; and a Bachelor of Science Degree in Biology and Chemistry each from Madras University, India. In addition, he has extensive training in Risk Management Systems and Medical Devices from Virginia Polytechnic and State University.

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radient-Pharma.com. For Investor Relations information contact Kristine Szarkowitz at IR@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical's current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Add to Digg Bookmark with del.icio.us Add to Newsvine